Patient info

Dapsone 50 mg tablets – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
50 mg
Contains active substance:
ATC code:

Patient leaflet - Dapsone 50 mg tablets

1. What Dapsone is and what it is used for

Dapsone belongs to a group of medicines called antibacterials. It works by stopping the production of folic acid in certain bacteria, therefore preventing them from growing.

Dapsone can be used to treat leprosy, to treat blistering skin disorders such as dermatitis herpetiformis (which is connected to gluten sensitivity) or to prevent pneumonia in immunodeficient patients (in particular patients with AIDS).

2. What you need to know before you take Dapsone

Do not take Dapsone:

  • if you are allergic to dapsone, sulfonamides, sulfones or any of the other ingredients of this medicine listed in section 6.
  • if you suffer from severe anaemia;
  • if you have porphyria (A group of rare inherited or acquired disorders where there is a problem with the production of haem (used to make haemoglobin in red blood cells) within the body);
  • if you suffer from severe glucose-6-phosphate dehydrogenase deficiency (A hereditary condition in which red blood cells break down when the body is exposed to certain medicines or infection).

Warnings and Precautions

Talk to your doctor or pharmacist before taking Dapsone if you:

  • suffer from other blood disorders;
  • suffer from heart or lung disorders.

Other medicines and Dapsone

Tell your doctor or pharmacist if you are taking any of the below listed medicines or if you have recently taken any other medicines, including medicines obtained without a prescription:

  • probenecid (to treat gout);
  • rifampicin or trimethoprim (to treat infections);

Driving and using machines

Dapsone has no known effect on the ability to drive or operate machinery.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy

There are no or very limited data from the use of dapsone in pregnant women.

The use of dapsone is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

Dapsone is excreted in breast milk.

Effects on the breastfed newborn/infant cannot be excluded.

3. How to take Dapsone

Always take Dapsone exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Swallow the tablets whole with a glass of water. The tablets can be divided into equal doses.

Unless otherwise prescribed by the doctor, the recommended doses are:

  • Adults and children (aged over 12 years):

    Multibacillary leprosy:

    100 mg daily for at least two years.

    Paucibacillary leprosy:

    100 mg daily for at least six months.

    Dermatitis herpetiformis:

    Initially 50 mg daily, which may be gradually increased to 300 mg daily and then reduced back down to the usual maintenance dose of 25 mg-50 mg daily.

    Pneumocystis carinii pneumonia:

    In combination with trimethoprim, 50-100 mg daily or 100 mg twice weekly or 200 mg once weekly.

  • Children aged 6-12 years:

    Multibacillary leprosy:

    50 mg daily for at least two years.

    Paucibacillary leprosy:

    50 mg daily for at least six months.

  • Elderly:

    If you have liver problems, your doctor may give you a lower dose.

If you take more Dapsone than you should

If you accidentally take more Dapsone than you should, contact your doctor or nearest hospital emergency department immediately for advice. Remember to take this leaflet or any remaining tablets with you.

Symptoms of overdose are: (low level of oxygen in the blood (hypoxia), methaemoglobinaemia (blood disorder in which an abnormal amount of methemoglobin (a form of haemoglobin) is produced) and haemolytic anaemia (reduction in red blood cells which can make the skin pale yellow and cause weakness or breathlessness).

If you forget to take Dapsone

Take it as soon as you remember, unless it is nearly time for your next dose. If you miss a dose, do not take a double dose to make up for a forgotten dose.

If you stop taking Dapsone

Do not stop taking Dapsone without first talking to your doctor. Your medicine may not work properly if you stop taking it too soon.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Dapsone can cause side effects, particularly when you first start taking it, although not everybody gets them.

Stop taking Dapsone and seek medical advice immediately if you develop the following symptoms:

  • Allergic reactions: swelling of the face, throat or tongue, fever, difficulty in breathing, dizziness.
  • Severe blistering of the skin, mouth, eyes and genitals (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis).
  • “Dapsone syndrome”. Fever, malaise, skin rashes, jaundice, swollen lymph glands, glandular fever, eosinophilia (increase in white blood cells), anaemia (low blood count) may occur.

Tell your doctor if you notice any of the following side effects or notice any other effects not listed in this leaflet:

Common (may affect up to 1 in 10 people):

  • Haemolysis (breakdown of red blood cells).
  • A blood disorder in which an abnormal amount of methemoglobin (a form of haemoglobin) is produced (methaemoglobinaemia).

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

Dapsone

50 mg and 100 mg

Tablets

Dapsone 50/100 mg Tablets

Package leaflet (POM)

L. 150 x H. 360 mm

L. 150 x H. 30 mm

510009506GB04

TW137596 (design)

UK

All

NA

TBA

9 points (Reg text)

510009506GB03 18/12/2023 22/12/2023

Black C

Emcure assembly

Uncommon (may affect up to 1 in 100 people):

  • Reduction in red blood cells which can make the skin pale yellow and cause weakness or breathlessness (haemolytic anaemia).
  • Faster heartbeat (tachycardia).

•Loss of appetite (anorexia).

  • Feeling or being sick (nausea, vomiting).
  • Inflammation of the liver (hepatitis).
  • Yellowing of skin or whites of the eyes (jaundice).
  • Changes in liver function tests.
  • Low levels of albumin in the blood

    (hypoalbuminaemia).

  • Headache.
  • Nerve damage affecting movement processes (peripheral neuropathy, peripheral motor neuropathy).
  • Difficulty in sleeping (insomnia).
  • Mental illness (psychosis).
  • Abnormal sensitivity of the skin to sunlight (photosensitivity).
  • Severe itching (pruritis).
  • Skin rash.

Rare (may affect up to 1 in 1,000 people):

  • Depletion of white blood cells (agranulocytosis).
  • Peeling of the skin over large areas of the body (exfoliative dermatitis).

Very rare (may affect up to 1 in 10,000 people):

  • A type of allergic reaction to a medicine causing skin lesions (fixed drug eruption).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. H ow to store Dapsone

Keep this medicine out of the sight and reach of children.

Do not use Dapsone after the expiry date which is stated on the label/carton. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Dapsone contains

  • The active substance is dapsone. Each tablet contains either 50 mg or 100 mg of dapsone.
  • The other ingredients are maize starch, silica colloidal anhydrous, magnesium stearate and microcrystalline cellulose.

What Dapsone looks like and contents of the pack

Dapsone Tablets come in aluminium and PVC/PVDC Unit Dose blister packs.

Dapsone 50 mg Tablets are available in packs of 28, 50 and 100 tablets.

Dapsone 100 mg Tablets are available in packs of 28 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Tillomed Laboratories Limited

220 Butterfield, Great Marlings

Luton, LU2 8DL, United Kingdom

This leaflet was last revised in 05/2023

Till-Ver.1

Hard to read?

To get this information in large print or another format, please email medical.information@tillomed.com or call 0800 970 6115.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 11311/0575

Last revision stated in the text: May 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Dapsone 50 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Dapsone
Strength 50 mg
Pharmaceutical form Oral tablet
White to off-white, uncoated, circular, biconvex tablets debossed "50" above and “D” below the score on one side and plain on the other side. Tablet size: 5.8 mm
The tablet can be divided into equal doses.
How is it taken Oral
Excipients Cellulose, microcrystalline (Grade – 102), Maize starch, Silica colloidal anhydrous, Magnesium stearate
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage condition.
Drug group (ATC) Anti-infectives for systemic use; anti-mycobacterials; drugs for treatment of lepra
  1. J Antiinfectives for systemic use
    1. J04 Antimycobacterials
      1. J04B Drugs for treatment of lepra
        1. J04BA Drugs for treatment of lepra
          1. J04BA02 dapsone
Marketing authorisation PL 11311/0575, PL 16363/0645 (first authorised 13 August 2026)
Marketing authorisation holder Milpharm Limited
Codes GTIN 5024655004300, 8901175055951 · BNF 05011000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.